Vedanta presents data from multiple studies at digestive disease week 2022 annual meeting

Cambridge, mass.--(business wire)--vedanta biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details of three podium presentations of research informed by multiple clinical studies at digestive disease week (ddw) 2022, being held both virtually and in person in san diego, ca on may 21-24. the analyses cover several defined bacterial consortia candidates developed by vedanta, and include
PRTC Ratings Summary
PRTC Quant Ranking